APOBEC3B: a potential factor suppressing growth of human hepatocellular carcinoma cells.
BACKGROUND
To realize the role of apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B (APOBEC3B) in hepatocellular carcinoma (HCC) occurrence, mRNAs of APOBEC3B from tumor and non-tumor tissues of patients with hepatectomy were isolated and in vitro studies were designed.


METHODS
Seventy-two tumor and non-tumor tissue samples, as well as clinical data, were collected from HCC patients during hepatectomy. The mRNA of APOBEC3B was assessed by real-time polymerase chain reaction. The viability of pLV-APOBEC3B-transfected Hep 3B cells was then determined. Cell growth of pLV-APOBEC3B-transfected Hep 3B cells was evaluated by in vitro migration assay.


RESULTS
The real-time polymerase chain reaction results indicated a higher expression of APOBEC3B mRNA in tumor tissues than in non-tumor tissues of patients with HBsAg+ HCC. The expression of APOBEC3B in tumor or non-tumor tissue was not found to be a risk factor of recurrence in patients with HCC. The cell viability assay results indicated the growth-inhibitory effects of APOBEC3B on Hep 3B cells. The cell migration results indicated that APOBEC3B inhibits wound healing in Hep 3B cells.


CONCLUSIONS
Based on these observations, we infer that APOBEC3B is a potential factor contributing to suppression of tumor growth in HCC.
Department of Kinesiology, Health and Leisure Studies, National University of Kaohsiung, Kaohsiung, Taiwan, R.O.C.
Pei-Fung
PF
Wu
Department of General Surgery, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan, R.O.C.
Yaw-Sen
YS
Chen
Department of Kinesiology, Health and Leisure Studies, National University of Kaohsiung, Kaohsiung, Taiwan, R.O.C.
Ting-Yin
TY
Kuo
Division of Infectious Diseases, Department of Internal Medicine, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan, R.O.C.
Hsi-Hsun
HH
Lin
School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
Ching-Wen
CW
Liu
Department of Occupational Therapy, I-Shou University, Kaohsiung, Taiwan, R.O.C. Department of Pharmacy, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan, R.O.C. changlc@isu.edu.tw.
Li-Ching
LC
Chang
D006528:Carcinoma, Hepatocellular / Q000473:pathology*; D045744:Cell Line, Tumor; D002465:Cell Movement; D003564:Cytidine Deaminase / Q000235:genetics / Q000502:physiology*; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology*; D015778:Minor Histocompatibility Antigens; D009364:Neoplasm Recurrence, Local / Q000209:etiology; D012333:RNA, Messenger / Q000032:analysis; D014945:Wound Healing
D015778:Minor Histocompatibility Antigens; D012333:RNA, Messenger; C495794:APOBEC3B protein, human; D003564:Cytidine Deaminase
Hep 3B; Hepatocellular carcinoma (HCC); apolipoprotein B mRNA editing enzyme; catalytic polypeptide-like 3B (APOBEC3B); vascular invasion